GNOG:LSE:LSE-Global X Genomics & Biotechnology UCITS ETF USD Acc GBP (GBP)

ETF | Others |

Last Closing

USD 5.916

Change

+0.02 (+0.29)%

Market Cap

USD 6.06M

Volume

909.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

-4.75 (-2.49%)

USD 1,607.29B
0R1O:LSE Amazon.com Inc.

-4.75 (-2.49%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

-0.84 (-0.70%)

USD 618.20B
0R1I:LSE NVIDIA Corp.

-0.84 (-0.70%)

USD 618.20B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

-0.05 (-0.38%)

USD 572.76B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

-0.05 (-0.38%)

USD 572.76B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.08 (-0.45%)

USD 572.76B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.08 (-0.45%)

USD 572.76B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B

ETFs Containing GNOG:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.19% 9% A- 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.19% 9% A- 22% F
Trailing 12 Months  
Capital Gain 1.96% 19% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.96% 17% F 30% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -13.21% N/A N/A 10% F
Dividend Return -13.21% N/A N/A 10% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 21.07% N/A N/A 46% F
Risk Adjusted Return -62.71% N/A N/A 12% F
Market Capitalization 6.06M 20% F 10% F

Annual Financials (GBP)

Quarterly Financials (GBP)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.